Skip to main content
Erschienen in: The Journal of Obstetrics and Gynecology of India 1/2016

17.12.2015 | Original Article

Correlation of Maternal Autoantibodies with Fetal Congenital Heart Block

verfasst von: Dey Madhusudan, Agarwal Raju, Nambula Vijaya

Erschienen in: The Journal of Obstetrics and Gynecology of India | Sonderheft 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Autoimmune fetal congenital heart block (CHB) is the most severe manifestation of neonatal lupus, and it is seen when maternal autoimmune antibodies cross the placenta and damage the AV node of the fetus. CHB is mainly associated with maternal SLE with anti-Ro/SSA- and anti-La/SSB-positive status, and incidence of CHB increases when both the antibodies are present. This study was conducted to know the incidence of fetal CHB in patients of SLE who had ANA, anti-Ro/SSA and anti-La/SSB positivity.

Methods

A prospective study was conducted in a tertiary-care teaching hospital of Indian Armed Forces between Jan 2012 to Sep 2014 where 13 cases of SLE were studied. All these patients were tested for ANA, anti-Ro/SSA and anti-La/SSB antibodies and fetal heart abnormalities. Fetuses with CHB were treated with steroids.

Results

Incidence of SLE was 0.14 %, 92 % of SLE patients were positive for ANA, and 46 % had anti-Ro/SSA- and anti-La/SSB-positive status. Two fetuses had congenital heart block, and one fetus required pacemaker placement 5 months after delivery.

Conclusion

All the fetal congenital heart blocks are associated with maternal anti-Ro/SSA and anti-La/SSB and ANA antibodies. Treatment by steroids may improve the outcome in early stages of fetal CHB, and delivery with follow-up should be planned in a tertiary-care center where pacemaker placement facility is available.
Literatur
1.
Zurück zum Zitat Wandstrat A, Wakeland E. The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat Immunol. 2001;2:802–9.CrossRefPubMed Wandstrat A, Wakeland E. The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat Immunol. 2001;2:802–9.CrossRefPubMed
2.
Zurück zum Zitat Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2002;16:847–8.CrossRefPubMed Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2002;16:847–8.CrossRefPubMed
3.
Zurück zum Zitat Alshohaib S. Outcome of pregnancy in patients with inactive systemic lupus erythematosus and minimal proteinuria. Saudi J Kidney Dis Trans. 2009;20(5):802–5. Alshohaib S. Outcome of pregnancy in patients with inactive systemic lupus erythematosus and minimal proteinuria. Saudi J Kidney Dis Trans. 2009;20(5):802–5.
4.
Zurück zum Zitat Brucato A, Doria A, Frassi G, et al. Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus. 2002;11:716–21.CrossRefPubMed Brucato A, Doria A, Frassi G, et al. Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus. 2002;11:716–21.CrossRefPubMed
5.
Zurück zum Zitat Carolis SD, Salvi S, Botta A, et al. Which intrauterine treatment for autoimmune congenital heart block? Open Autoimmun J. 2010;2:1–10. Carolis SD, Salvi S, Botta A, et al. Which intrauterine treatment for autoimmune congenital heart block? Open Autoimmun J. 2010;2:1–10.
6.
Zurück zum Zitat Friedman DM, Kim MY, Copel JA, et al. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol. 2009;103(8):1102–6.CrossRefPubMedPubMedCentral Friedman DM, Kim MY, Copel JA, et al. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol. 2009;103(8):1102–6.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Clowes ME, Jamison M, Myers E, et al. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol. 2008;199:127e1.CrossRef Clowes ME, Jamison M, Myers E, et al. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol. 2008;199:127e1.CrossRef
8.
Zurück zum Zitat Brucato A, Garva C, Bortolati M, et al. Congenital heart block not associated with Anti-Ro/La antibodies: comparison with anti-Ro/La-positive cases. J Rheumatol. 2009;36(8):1744–8.CrossRefPubMedPubMedCentral Brucato A, Garva C, Bortolati M, et al. Congenital heart block not associated with Anti-Ro/La antibodies: comparison with anti-Ro/La-positive cases. J Rheumatol. 2009;36(8):1744–8.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Nield LE, Silverman ED, Smallhorn JF, et al. Endocardial fibroelastosis associated with maternal anti-Ro and antiLa antibodies in the absence of atrioventricular block. Circulation. 2002;40:796–802. Nield LE, Silverman ED, Smallhorn JF, et al. Endocardial fibroelastosis associated with maternal anti-Ro and antiLa antibodies in the absence of atrioventricular block. Circulation. 2002;40:796–802.
10.
Zurück zum Zitat BramhamK K, Soh MC, Nelson-Piercy C. Pregnancy and renal outcomes in lupus nephritis: an update and guide to management. Lupus. 2012;21(12):1217. BramhamK K, Soh MC, Nelson-Piercy C. Pregnancy and renal outcomes in lupus nephritis: an update and guide to management. Lupus. 2012;21(12):1217.
11.
Zurück zum Zitat Horsfall AC, Li JM, Maini RN. Placental and fetal cardiac laminin are targets for cross-reacting autoantibodies from mothers of children with congenital heart block. J Autoimmun. 1996;9(4):561–8.CrossRefPubMed Horsfall AC, Li JM, Maini RN. Placental and fetal cardiac laminin are targets for cross-reacting autoantibodies from mothers of children with congenital heart block. J Autoimmun. 1996;9(4):561–8.CrossRefPubMed
12.
Zurück zum Zitat Friedman DM, Llanos C, Izmirly PM, et al. Evaluation of fetuses in the preventive IVIG therapy for congenital heart block (PITCH) study. Arthritis Rheum. 2010;62(4):1138–46.CrossRefPubMedPubMedCentral Friedman DM, Llanos C, Izmirly PM, et al. Evaluation of fetuses in the preventive IVIG therapy for congenital heart block (PITCH) study. Arthritis Rheum. 2010;62(4):1138–46.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Costedoat-Chalumeau N, Amoura Z, Le Thi Hong D, et al. Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis. 2003;62:1010–2.CrossRefPubMed Costedoat-Chalumeau N, Amoura Z, Le Thi Hong D, et al. Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis. 2003;62:1010–2.CrossRefPubMed
14.
Zurück zum Zitat Puria S, Pooni P, Mohan B, et al. Pregnancy with SLE and fetal congenital heart block: a case report. Cardiol Res. 2013;4:126–8. Puria S, Pooni P, Mohan B, et al. Pregnancy with SLE and fetal congenital heart block: a case report. Cardiol Res. 2013;4:126–8.
Metadaten
Titel
Correlation of Maternal Autoantibodies with Fetal Congenital Heart Block
verfasst von
Dey Madhusudan
Agarwal Raju
Nambula Vijaya
Publikationsdatum
17.12.2015
Verlag
Springer India
Erschienen in
The Journal of Obstetrics and Gynecology of India / Ausgabe Sonderheft 1/2016
Print ISSN: 0971-9202
Elektronische ISSN: 0975-6434
DOI
https://doi.org/10.1007/s13224-015-0813-7

Weitere Artikel der Sonderheft 1/2016

The Journal of Obstetrics and Gynecology of India 1/2016 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.